Daniela Malengo | Pharmacology | Women Researcher Award

Posted on by ScienceFather

Dr. Daniela Malengo | Pharmacology | Women Researcher Award

Dr at Istituto Europeo di Oncologia, Italy

Daniela Malengo, an Italian pharmacist, is currently the Vice Director of the Hospital Pharmacy Division at Istituto Europeo di Oncologia, Milan. With a career spanning over 15 years, Daniela specializes in oncology drug management, hospital pharmacy administration, and medical device protocols. She is passionate about optimizing pharmaceutical practices and contributing to oncology care. Throughout her career, she has been dedicated to ensuring the safe and effective use of drugs in oncological treatments and has supported numerous research projects. Her leadership skills also extend to teaching pharmacy students through internships and projects.

Profile

Scopus

šŸŽ“ EducationĀ 

Management of CAR-T Patients, LIUC Business School (Dec 2023ā€“Mar 2024). Hospital Pharmacy Management, UniversitĆ  Bocconi, Milan (Sept 2019ā€“Dec 2020). Specialization in Applied Pharmacology, University of Pavia (2005ā€“2009). Degree in Pharmacy, University of Pavia (2000ā€“2005). State Exam for Pharmacist License, University of Pavia (Novā€“Dec 2005). Scientific High School Diploma, Liceo Scientifico N. Copernico, Pavia (1995ā€“2000)

šŸ’¼ Experience

Vice Director of Hospital Pharmacy Division, Istituto Europeo di Oncologia, Milan (July 2023ā€“Present): Managing narcotic drug dispensation and overseeing oncological therapy. Assistant Pharmacist, Istituto Europeo di Oncologia, Milan (Mar 2011ā€“July 2023): Managed medical devices and chemotherapy prescriptions. Pharmacist ā€“ Research Fellow, Istituto Europeo di Oncologia, Milan (May 2006ā€“Feb 2011): Supervised experimental drugs and contributed to research on oncological drug appropriateness. Intern (2004ā€“2005): Worked at Farmacia Dott. A. Lodola, Siziano, dispensing medications to the public.

šŸ† Awards & Honors

Numerous presentations at national congresses, including SIFO Congress (2009ā€“2010). Recognized for contributions to hospital pharmacy management and cost analysis of oncological treatments. Leadership roles in pharmacy student internships and research programs. Awarded for excellence in promoting safe oncological drug usage.

šŸ”¬ Research Focus

Oncology Pharmacology: Focuses on managing oncological drug appropriateness, chemotherapy prescriptions, and medical device protocols. Pharmacy Management: Expertise in hospital pharmacy operations, including drug dispensation, quality control, and patient safety. Experimental Pharmacology: Managed experimental drugs and contributed to clinical research in oncological treatments. Cost Analysis: Focus on managing hospital pharmacy expenses and evaluating drug cost-effectiveness.

Conclusion

Daniela Malengo’s career exemplifies dedication to hospital pharmacy, oncological drug management, and the advancement of healthcare systems through her research and leadership roles. Her consistent contributions to improving patient outcomes in oncology, coupled with her academic excellence, make her a strong candidate for the Women Researcher Award. With her continued focus on improving the quality of healthcare services and mentoring future professionals, Danielaā€™s future contributions are poised to have a lasting impact in both the pharmacy and healthcare sectors.

šŸ“šPublicationsĀ 

  • The Prolonged Clinical Benefit with Metronomic Chemotherapy (VEX Regimen) in Metastatic Breast Cancer Patients
    • Authors: Montagna, E., Pagan, E., Cancello, G., Viale, G., Colleoni, M.
    • Journal: Anti-Cancer Drugs
    • Volume: 33
    • Issue: 1
    • Pages: E628ā€“E634
    • Year: 2022
    • Citations: 6

 

  • Management of Breast Cancer Patients During the Peak of the COVID-19 Pandemic
    • Authors: Montagna, E., Bellerba, F., Sangalli, C., Colleoni, M., Veronesi, P.
    • Journal: European Journal of Surgical Oncology
    • Volume: 47
    • Issue: 10
    • Pages: 2694ā€“2695
    • Year: 2021
    • Citations: 2

 

Srijan Acharya | Molecular Pharmacology | Excellence in Research

Posted on by ScienceFather

Dr. Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr at St. Jude Children’s Research Hospital, United States

Srijan Acharya is a dedicated scientist with expertise in molecular pharmacology and cancer genomics. He is currently a Post-Doctoral Research Fellow at St. Jude Childrenā€™s Research Hospital, focusing on childhood cancer research. With 32 published scientific articles and a total citation count of over 385, his work has contributed significantly to biomarker discovery, receptor pharmacology, and immuno-oncology. His research aims to address therapeutic resistance in pediatric malignancies through small molecule screening. Srijan is fluent in English, Bangla, and Hindi, with basic knowledge of Korean.

Profile

Scholar

šŸŽ“ Education

PhD in Molecular Pharmacology from Chonnam National University, South Korea (2020). M.Sc. in Biotechnology from North South University, Bangladesh (2015). BPHRM in Pharmacy from East West University, Bangladesh (2012). His academic journey has provided a strong foundation in receptor pharmacology and molecular biology, guiding his transition into cancer research.

šŸ’¼ Experience

Post-Doctoral Research Fellow, Pharmacy Department, St. Jude Childrenā€™s Research Hospital, USA (2023-Present). Post-Doctoral Research Fellow, Pathology Department, Mitchell Cancer Institute, USA (2020-2023). Executive Officer, Research and Development, Square Pharmaceutical PLC, Bangladesh (2012-2013). His experience spans academia and industry, with a focus on cancer research, receptor signaling, and small molecule screening.

šŸ† Awards and Honors

Inducted into Sigma Xi, The Scientific Research Honor Society (2023). Recognized in Whoā€™s Who in America by Marquis (2023). Young Investigator Award at AACR conference by AAISCR (2022). Best Presenter Award from China Pharmaceutical University (2021). Global Scholarship from Chonnam National University, Korea (2015). These accolades reflect his significant contributions to molecular pharmacology and cancer research.

šŸ”¬ Research Focus

Srijanā€™s research primarily investigates the role of molecular signaling in cancer, focusing on the interaction of nicotine receptors with GPCRs and their impact on cancer progression. At St. Jude, his work focuses on childhood cancers, particularly Ewing sarcoma and rhabdomyosarcoma. He uses small molecule screening to discover potential therapeutic agents and aims to overcome therapeutic resistance in pediatric cancers.

Conclusion

Srijan Acharya is a highly accomplished and promising researcher whose contributions to cancer pharmacology and molecular biology are noteworthy. His interdisciplinary research approach, combined with his dedication to advancing pediatric oncology, positions him as a leader in the field. With continued mentorship and broader collaborative efforts, Acharya is well poised for even greater achievements, further solidifying his place as an influential scientist in the biomedical community.

šŸ“šPublicationsĀ 

  • Title: Unveiling the intracellular dynamics of Ī±4Ī²2 nAChR-mediated ERK activation through the interplay of arrestin, GĪ²Ī³, and PKCĪ²II
    Year: 2024
    Authors: Dooti K, Acharya S, Wang S, Kim K.M.

 

  • Title: Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer
    Year: 2023
    Authors: Acharya S, Anand S, Khan MA, Zubair H, Srivastava SK, Singh S, Singh AP

 

  • Title: MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer
    Year: 2023
    Authors: Md Khan, S Acharya, S Anand, F Sameeta, P Pramanik, C Keel, S Singh, James E Carter, S Dasgupta, A Singh

 

  • Title: Comparative study of the molecular mechanisms underlying the G protein and Ī²-arrestin-dependent pathways that lead to ERKs activation upon stimulation by dopamine D2 receptor
    Year: 2023
    Authors: Liu H, Acharya S, Sudan SK, Hu L, Wu C, Cao Y, Li H, Zhang X

 

  • Title: Frequent loss of cacna1c, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis
    Year: 2023
    Authors: Dasgupta, S., Acharya, S., Khan, M. A., Pramanik, P., Marbut, S. M., Yunus, F., Galeas, J. N., Singh, S., Singh, A. P., and Dasgupta, S.

 

  • Title: Nicotine causes alternative polarization of macrophages via Src-mediated STAT3 activation: Potential pathobiological implications
    Year: 2022
    Authors: Acharya S, Saranyutanon S, Deshmukh SK, Khan MA, Singh S, Singh AP

 

  • Title: Ī²-Arrestin1 and GRK2 play permissive roles in Src-mediated endocytosis of Ī±4Ī²2 nicotinic acetylcholine receptor
    Year: 2021
    Authors: Acharya S, Kundu D, Kim KM

 

  • Title: Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease
    Year: 2021
    Authors: Acharya S, Kim KM

 

  • Title: Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer
    Year: 2021
    Authors: Miree, O., Srivastava, ā€¦Acharya S.et al.

 

  • Title: Metabotropic signaling cascade involved in Ī±4Ī²2 nicotinic acetylcholine receptor-mediated PKCĪ²II activation
    Year: 2020
    Authors: Acharya S, D. Kundu, H.J. Choi, and K.M. Kim

 

  • Title: Catalpol and Mannitol, Two Components of Rehmannia glutinosa, Exhibit Anticonvulsant Effects Probably via GABAA Receptor Regulation
    Year: 2019
    Authors: Acharya S, Kim M., Botanas C. J., Custodio R. J., Lee H. J., Sayson L. V., Kim H. J.

 

  • Title: Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
    Year: 2017
    Authors: Paudel S, Acharya S, Yoon G, Kim K.M., & Cheon S.H.